Literature DB >> 7815145

Deep central arteriovenous malformations of the brain: the role of endovascular treatment.

R W Hurst1, A Berenstein, M J Kupersmith, M Madrid, E S Flamm.   

Abstract

Cerebral deep central arteriovenous malformations (AVMs) are uncommon lesions associated with considerable difficulty in treatment. The authors report a series of 14 deep central AVMs treated by endovascular methods and examine the present role of endovascular treatment. This treatment used alone resulted in complete obliteration of AVMs in approximately 15% of case and reduction in 50% to a size permitting treatment by means of radiosurgery. Reversal of previous neurological signs and symptoms occurred in 35.7% of embolized patients. Overall, nearly 80% of patients had either complete obliteration of the lesion, reduction to a size allowing radiosurgical treatment, or reversal of previous neurological deficits. There were treatment complications in 14.3% of the cases. Endovascular treatment methods may make a significant contribution to the therapy of AVMs that have a particularly poor course and are difficult to treat by other means.

Entities:  

Mesh:

Year:  1995        PMID: 7815145     DOI: 10.3171/jns.1995.82.2.0190

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

1.  Complete obliteration of intracranial arteriovenous malformation with endovascular cyanoacrylate embolization: initial success and rate of permanent cure.

Authors:  Simon C H Yu; Michael S Y Chan; Joseph M K Lam; Patrick H T Tam; Wai S Poon
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

2.  The Preoperative Functional Downgrading of Brain AVMs.

Authors:  Sabino Luzzi; Mattia Del Maestro; Renato Galzio
Journal:  Acta Neurochir Suppl       Date:  2021

Review 3.  Endovascular management of arteriovenous malformations of the brain.

Authors:  Charles A Bruno; Philip M Meyers
Journal:  Interv Neurol       Date:  2013-09

4.  Predictors of total obliteration in endovascular treatment of cerebral arteriovenous malformations.

Authors:  José Antonio Jordan; Juan Carlos Llibre; Frank Vazquez; Raul Marino Rodríguez
Journal:  Neuroradiol J       Date:  2014-02-24

5.  Quantitative assessment of polymerization-binding mechanics of cyanoacrylates: model development and validation.

Authors:  Purushothaman Kailasnath; John C Chaloupka
Journal:  AJNR Am J Neuroradiol       Date:  2002-05       Impact factor: 3.825

6.  Ventricular/paraventricular small arteriovenous malformations: role of embolisation with cyanoacrylate.

Authors:  Ismail Oran; Mustafa Parildar; Abdurrahim Derbent
Journal:  Neuroradiology       Date:  2005-04-02       Impact factor: 2.804

7.  Nidal embolization of brain arteriovenous malformations using Onyx in 94 patients.

Authors:  C Mounayer; N Hammami; M Piotin; L Spelle; G Benndorf; I Kessler; J Moret
Journal:  AJNR Am J Neuroradiol       Date:  2007-03       Impact factor: 3.825

8.  Provocative test with propofol: experience in patients with cerebral arteriovenous malformations who underwent neuroendovascular procedures.

Authors:  C E Feliciano; R de León-Berra; M S Hernández-Gaitán; H M Torres; O Creagh; R Rodríguez-Mercado
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-05       Impact factor: 3.825

9.  Adjuvant embolization with N-butyl cyanoacrylate in the treatment of cerebral arteriovenous malformations: outcomes, complications, and predictors of neurologic deficits.

Authors:  Robert M Starke; Ricardo J Komotar; Marc L Otten; David K Hahn; Laura E Fischer; Brian Y Hwang; Matthew C Garrett; Robert R Sciacca; Michael B Sisti; Robert A Solomon; Sean D Lavine; E Sander Connolly; Philip M Meyers
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

10.  Endovascular treatment of deep hemorrhagic brain arteriovenous malformations with transvenous onyx embolization.

Authors:  A Consoli; L Renieri; S Nappini; N Limbucci; S Mangiafico
Journal:  AJNR Am J Neuroradiol       Date:  2013-04-04       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.